Medicinova (MNOV)
NASDAQ:MNOV
MNOV Stock Chart & Stats
$1.44
-$0.10(-4.76%)
At close: 4:00 PM EST
$1.44
-$0.10(-4.76%)
Day’s Range― - ―
52-Week Range$1.17 - $1.96
Previous CloseN/A
Volume15.80K
Average Volume (3M)1.79M
Market Cap
$62.51M
Enterprise Value-$27.10B
Total Cash (Recent Filing)$27.33M
Total Debt (Recent Filing)$165.20K
Price to Earnings (P/E)―
Beta0.14
Next EarningsN/A
EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.24
Shares Outstanding49,221,245
10 Day Avg. Volume177,340
30 Day Avg. Volume1,788,408
Financial Highlights & Ratios
PEG Ratio-1.23
Price to Book (P/B)1.55
Price to Sales (P/S)156.89
P/FCF Ratio-6.55
Enterprise Value/Market Cap-433.48
Enterprise Value/Revenue-45.42K
Enterprise Value/Gross Profit-298.83K
Enterprise Value/Ebitda2.15K
Forecast
1Y Price Target
$8.00Price Target Upside455.56% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
EPS Forecast (FY)-0.29
Revenue Forecast (FY)$221.75K
Medicinova News
MNOV FAQ
What was Medicinova’s price range in the past 12 months?
Medicinova lowest stock price was $1.17 and its highest was $1.96 in the past 12 months.
What is Medicinova’s market cap?
Medicinova’s market cap is $62.51M.
When is Medicinova’s upcoming earnings report date?
The company’s upcoming earnings report date is not yet available.
How were Medicinova’s earnings last quarter?
Medicinova released its earnings results on Jul 27, 2022. The company reported -$0.15 earnings per share for the quarter, missing the consensus estimate of -$0.087 by -$0.063.
Is Medicinova overvalued?
According to Wall Street analysts Medicinova’s price is currently Undervalued.
Does Medicinova pay dividends?
Medicinova does not currently pay dividends.
What is Medicinova’s EPS estimate?
Medicinova’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Medicinova have?
Medicinova has 49,221,245 shares outstanding.
What happened to Medicinova’s price movement after its last earnings report?
Medicinova reported an EPS of -$0.15 in its last earnings report, missing expectations of -$0.087. Following the earnings report the stock price went down -1.835%.
Which hedge fund is a major shareholder of Medicinova?
Currently, no hedge funds are holding shares in MNOV
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Medicinova Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Positive
20 days / 200 days
Momentum
-30.28%
12-Months-Change
Fundamentals
Return on Equity
-0.12%
Trailing 12-Months
Asset Growth
-18.55%
Trailing 12-Months
Company Description
Medicinova
MediciNova, Inc. is a biopharmaceutical firm dedicated to discovering and advancing innovative small molecule therapies for severe illnesses where current treatments are insufficient within the United States. Its robust development pipeline features MN-166 (ibudilast), an oral agent with both anti-inflammatory and neuroprotective properties, currently being investigated for a range of neurological conditions. These include primary and secondary progressive multiple sclerosis, amyotrophic lateral sclerosis, chemotherapy-induced peripheral neuropathy, degenerative cervical myelopathy, glioblastoma, and various forms of substance dependence and addiction. The company's portfolio also comprises MN-221 (bedoradrine), a selective beta-2-adrenergic receptor agonist aimed at treating acute asthma attacks; MN-001 (tipelukast), an orally available small molecule designed for fibrotic disorders like nonalcoholic steatohepatitis and idiopathic pulmonary fibrosis; and MN-029 (denibulin), a tubulin binding agent intended for solid tumor oncology. MediciNova has established strategic partnerships with companies such as Kissei Pharmaceutical Co., Ltd., Kyorin Pharmaceutical Co., Ltd., Angiogene Pharmaceuticals Ltd., and Meiji Seika Kaisha Ltd. Established in 2000, the company's headquarters are situated in La Jolla, California.
MNOV Stock 12 Month Forecast
Average Price Target
$8.00
▲(455.56% Upside)
Technical Analysis
Precision BioSciences
―
Aligos Therapeutics
―
Genenta Science SpA Sponsored ADR
―
Acrivon Therapeutics, Inc.
―
CAMP4 Therapeutics Corporation
―
Ownership Overview
2.87%
Insiders
2.37% Mutual Funds
2.36% Other Institutional Investors
90.89% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---